Farooq A Wandroo

Hon.Assoc.Professor
Univ of Birmingham,Head of Haematolgy, SWBH NHS Trust,interests in Myeloma/Lymph/leukemia,cricket, believes in duty of care@bkcf@bkma

[Farooq A Wandroo @FWANDROO]

We did it again
@djnicholl @DavidNichols0n @NHSBeeky @SWBHnhs @SWBH_RandD @DrDerekConnolly @DrChetanVarma @doc_hnaqvi @bkma_the
Surgeons have to wait

[david nicholson @DavidNichols0n]

The end of exciting innings physicians 154 for 4 after 20 overs

[Farooq A Wandroo @FWANDROO]

Yes absolutely as per DREAM trials -incidentally we are in Lisbon with your US colleagues discussing the same

[Farooq A Wandroo @FWANDROO]

Thanks
Why not BVD/BPD as 2nd line ( if Carflizomib not an option)

[Vincent Rajkumar @VincentRK]

With 20 new drug approvals in 20 years, the treatment of relapsed myeloma may appear complex and daunting. Here is a simple way to approach your patient.

In first relapse, you essentially 3 main choices: CART (ciltacel), Tec-Dara, or one of the standard triplets (DPd, DKd, etc).

In second or later relapse, you have an additional key choice, belantamab.

If the patient is not refractory to dara, omit the dara; bispecific alone or non-dara containing triplet (eg KPd).

How to choose?

We usually decide among these 3-4 key options based on patient choice and feasibility. Some patients may prefer the one shot approach with CART. In some, the disease is too aggressive to consider CART. In some, CART or bispecifics may just not be feasible or available and you have to go with triplet or belantamab.

https://t.co/SRJelvwfKj

[Farooq A Wandroo @FWANDROO]

@GSK

[Farooq A Wandroo @FWANDROO]

Paul Richardson summary on Dream trials and journey of Belamaf in Myeloma in 2nd line Rx
@ASH_hematology @BritSocHaem @MidlandMetUH @swbohw @SWBHnhs

[Farooq A Wandroo @FWANDROO]

Paul Richardson summary on Dream trials and journey of Belamaf in Myeloma in 2nd line Rx
@ASH_hematology @BritSocHaem @MidlandMetUH @swbohw @SWBHnhs

[Farooq A Wandroo @FWANDROO]

GSK
International myeloma meeting, connecting dots
Saad Usmani chairing
All about Dream trials and 2nd line Rx @szusmani @ASH_hematology @BritSocHaem @MidlandMetUH @SWBHnhs

[Toby Eyre @tobyeyre82]

Draft @NICEComms guidance for #pirtobrutinib
Provisionally approved for
R/R CLL
Post cBTKI
Ven Exposed or Naive
Final guidance pending #CLL #pirtobrutinib

[Farooq A Wandroo @FWANDROO]

Great talk by Charlie Craddock
Summary slide
Indications for Allograft in AMl @BritSocHaem @charliecraddock @SWBHnhs @MidlandMetUH

[Farooq A Wandroo @FWANDROO]

Learning from AML at BSH
50 mg may be the best dose for venetoclax if on Azoles

[Farooq A Wandroo @FWANDROO]

Indirect comparison of Ciltacel Vs current 2ndlline regimens ( dvd,pvd,BPd)
Again citadel stands out
But not compared with Bispecific data ( eg majestic 3)
@bloodmed @BritSocHaem @drKamarajk @swbohw @MidlandMetUH

[Farooq A Wandroo @FWANDROO]

Majestic -3
30mth fup at BSH , TEC - Dara impressive PFS and OS post 1-3 lines of Len exposed / refractory Myeloma
Across all groups
? New SOC at ist relapse
Await NICE
@BritSocHaem
@SWBHnhs @MidlandMetUH @bloodmed @SalimShafeek5

[The BMJ @bmj_latest]

NEW BMJ Research: Weight regain after cessation of medication for weight management
https://t.co/EGtJiTeaog
@_WestSam

Linked Editorial exploring how weight management drugs are no magic bullets for treating obesity
https://t.co/E4Zcq4Di0D

[Farooq A Wandroo @FWANDROO]

Good note to end the year
I spoke to this 89 year old , one of first few elderly AML pts Rx with AZA/Ven, (AXL Mut)
In remission off Rx for 2 years, who would have imagined a few years ago !
Power of science @ASH_hematology
@SWBHnhs
@BritSocHaem

[Farooq A Wandroo @FWANDROO]

@MorphologyAmigo @DrNikitaMehra @DrAkhilX @nihardesai89 By the way
This is the current algorithm for managing ITP
There is one drug missing presented at ASH Ianalumab (anti BAFF)

[Farooq A Wandroo @FWANDROO]

Guidance on recording consultations, https://t.co/G8IEiLfr0p @SWBHnhs @MidlandMetUH @bmj_latest @bkma_the

[British Journal of Haematology @BrJHaem]

🔹 @BritSocHaem Guideline🔹
Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline
https://t.co/MYWkIr5rHd

[Farooq A Wandroo @FWANDROO]

Lovely drink I know it ,but keep your country cricketers away, they will make a mess

[Talha Badar @TalhaBadarMD]

Fantastic gift from a friend and a colleague!

Tried the new treatment called cricket.

Mood improved.

Happiness achieved.

Science confirmed. 🏏😄 #cricket

[Farooq A Wandroo @FWANDROO]

I take you seriously @VincentRK
I post what may be practice influencing or educationally fascinating

[Vincent Rajkumar @VincentRK]

I need to follow a 100 more people posting on hematology and oncology. #ASH25

Give me some suggestions.

[Talha Badar @TalhaBadarMD]

#ASH25 Key abstract to watch in acute myeloid leukemia #AML #leusm 🧵

Overall Takeaways

#Menin_inhibitors (revumenib, ziftomenib, enzomenib) are rapidly emerging as key agents in both frontline and R/R AML.

Triplet regimens (VEN/AZA + targeted therapy) show promise across AML subtypes.

Novel immunotherapies (bispecific FLT3×CD3) and CD123-directed therapy continue to expand the therapeutic landscape.

Real-world data in TP53-mutant AML remain critical for optimizing HMA selection.

[Farooq A Wandroo @FWANDROO]

This is fascinating,brilliant work by Dr Fathi et all
Challenge to 50 yr old 7+3 regimen for AML
@MorphologyAmigo
@ASH_hematology #Ash25
@BritSocHaem

[Talha Badar @TalhaBadarMD]

#ASH25 #ASHPlenary
#PARADIGM trial
Great work, congratulations to Dr. Fathi and colleagues! #AML #leusm
Summary:
The study met PE for EFS.
Higher ORR and CR in VEN+AZA gp
More pt received transplant in VEN+AZA gp
Better QOL

[Farooq A Wandroo @FWANDROO]

I m virtual for a change
#ASH25, I will follow the science

[ASH @ASH_hematology]

A little behind the scenes at #ASH25 because so much heart goes into bringing this meeting to life. #ASHkudos to the crew behind the build and to the amazing attendees who make this meeting feel alive.

#Hematology #HemeOnc